This novel regulatory role of CaM in the DR5-associated DISC may present a unique opportunity for the use of these readily available and well tolerated CaM antagonists, TMX and TFP, in combination with DR5 agonists to enhance the therapeutic efficacy of TRAIL-resistant pancreatic cancer. The gene discussed is TNFSF10; the disease is familial pancreatic carcinoma.